Jennifer Chu is a corporate partner and member of the firm’s Mergers & Acquisitions and Private Equity Groups. Her practice focuses on advising corporations and private equity firms in mergers and acquisitions, joint ventures and other corporate matters, across a broad range of industries with a particular focus on transactions in the healthcare, financial services and insurance industries. Ms. Chu is recommended by Chambers Global (2022) and Chambers USA (2022), where clients note that she is “a fantastic adviser and counselor” who is “incredibly detail-oriented and has a good sense of how to think about risk and understanding of what kind of risks to take.” She is also recognized as a Leading Lawyer for private equity buyouts and recommended for Healthcare: Life Sciences by The Legal 500 US (2022). She co-led The Deal’s “Private Equity Deal of the Year” (2018) for representing TPG Capital and Welsh, Carson, Anderson & Stowe, with Humana, in their $4.1 billion acquisition of Kindred Healthcare. Ms. Chu is recognized as a leading M&A and private equity lawyer by IFLR1000 (2020) and as a Rising Star by Law360 (2019). She was also named to Crain’s New York Business’s 2019 list of “Notable Women in Law” and selected as a Rising Star by the New York Law Journal (2017).
Ms. Chu publishes and speaks regularly on M&A and private equity matters. She is a contributing author to the annual Health Care Mergers and Acquisitions Answer Book (Practising Law Institute, 2019), an extensive reference guide addressing structuring, regulatory, due diligence and documentation issues in healthcare M&A and licensing transactions. Her articles include: co-author of “Locked Boxes in U.S. Practice: An Underused Tool?” The M&A Lawyer (June, 2021); “How Tax Reform Could Impact the Healthcare Industry,” Law360 (November, 2017); “How Section 1332 Waivers Could Impact Health Care Reform,” Law360 (July, 2017); “Shining a Light on GOP Plan for Health Care Reform,” Law360 (March, 2017); “The Outlook For The Pharmaceutical Industry Under Trump,” Law360 (January, 2017); “The Outlook on Drug Pricing: At What Cost?,” Law360 (December, 2016); and “A Closer Look: Increased Cybersecurity Regulations are Impacting the Insurance and Financial Technology Sectors,” Best's Review (June, 2015). She is an editor of The Debevoise & Plimpton Private Equity Report.
Ms. Chu’s recent speaking engagements include “Indemnification Issues,” Acquiring and Selling the Privately Held Company 2018 (June, 2018); “Techniques and Issues in Negotiating Indemnification Provisions, Including: “Baskets,” “Caps,” “Sandbagging,” Materiality Scrapes and Survival of Warranties,” Acquiring and Selling the Privately Held Company 2017 (June, 2017); and “Health Care M&A: Three Hot Topics,” PLI One-Hour Briefing (April, 2017).
Ms. Chu is actively involved in the development of young lawyers, particularly women and diverse lawyers. She co-chairs Debevoise’s Women’s Resource Group and is a member of its Diversity Committee. She serves on the Board of Directors of Practicing Attorneys for Law Students, a not-for-profit organization focusing on enhancing the skills and careers of minority law students and early career lawyers through mentoring, education and professional development opportunities. She has spoken on panels about women in the legal profession, including at the Annual Conference of the National Association of Women Lawyers and at Harvard Law School. She is also a 2015 Alumni of the Fellows Program of the Leadership Council on Legal Diversity, an organization of leading corporate chief legal officers and law firm managing partners.
Ms. Chu joined the firm in 2006. She received her J.D. cum laude from Harvard Law School in 2006, where she served as co-editor-in-chief of the Harvard International Law Journal. She received her M.A. with distinction from the University of London in 2002, and her A.B. magna cum laude from Harvard College in 2001.
Ms. Chu is a member of the Bar of New York.